Tom Reuvekamp

10PUBLICATIONS
45CO-AUTHORS
Medical mycologyHaematological tumoursMedical virologyRegenerative medicine (incl. stem cells)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 08, 2026
Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies.

|Mar 19, 2026
Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy.

Lukas H Haaksma, Tom Reuvekamp, Kasper J Croese

|Dec 15, 2025
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

Jacqueline Cloos, Peter J M Valk, Christian Thiede

|Dec 10, 2025
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.

Lukas H Haaksma, Raffaele Palmieri, Tom Reuvekamp

|Sep 03, 2025
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial.

Tim R Mocking, Lukas H Haaksma, Tom Reuvekamp

|Jul 14, 2025
Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T-cell therapy.

Jort J van der Schans, Paresh Vishwasrao, Renée Poels

Pageof 2

Frequent Collaborators

6 joint publications

Costa Bachas

6 joint publications

Jacqueline Cloos

4 joint publications

Lok Lam Ngai

4 joint publications

David C de Leeuw